首页 > 最新文献

European Journal of Cancer (1965)最新文献

英文 中文
Putrescine diffusion in cat brain and capillary permeability in rat brain: Relation to CSF putrescine levels in brain tumor patients 猫脑腐胺扩散及大鼠脑毛细血管通透性:与脑肿瘤患者脑脊液腐胺水平的关系
Pub Date : 1981-02-01 DOI: 10.1016/0014-2964(81)90028-1
Enrico Pierangelli , Victor A. Levin , Jerome Seidenfeld , Laurence J. Marton

Cerebrospinal fluid (CSF) putrescine (Pu) levels are extremely useful measures of active tumor growth in patients harboring medulloblastoma but not in patients harboring most supratentorial malignant gliomas. This study was designed to determine the diffusion coefficient (D) for Pu in cat brain and the capillary permeability coefficient (Pc) in rat brain to explain the failure of supratentorial gliomas to manifest a consistent increase in CSF Pu with progressive tumor growth. The Pc for Pu was found to be greater than the Pc for urea, while the apparent brain D for Pu was lower than that for urea. This implies that Pu crosses capillaries and enters cells more rapidly than urea, which would reduce the amount of Pu that might ultimately reach the CSF by diffusion from tumor. These data explain why CSF levels of Pu are correlated best in medulloblastoms—generally located adjacent to the CSF pathways—and why levels are correlated least in malignant supratentorial gliomas—usually located within the brain hemispheres, from which diffusion to the ventricles and into the CSF would be difficult.

脑脊液腐胺(Pu)水平对髓母细胞瘤患者的活动性肿瘤生长非常有用,但对大多数幕上恶性胶质瘤患者则无效。本研究旨在测定Pu在猫脑中的扩散系数(D)和大鼠脑中的毛细血管渗透系数(Pc),以解释幕上胶质瘤不能随着肿瘤的进展而表现出脑脊液Pu的一致增加。结果表明,Pu的Pc值大于尿素,而Pu的表观脑D值低于尿素。这意味着Pu穿过毛细血管进入细胞的速度比尿素快,这将减少可能最终通过肿瘤扩散到达脑脊液的Pu的数量。这些数据解释了为什么Pu水平在髓母细胞(通常位于脑脊液通路附近)中相关性最好,而在恶性幕上胶质瘤(通常位于大脑半球内,难以扩散到脑室并进入脑脊液)中相关性最低。
{"title":"Putrescine diffusion in cat brain and capillary permeability in rat brain: Relation to CSF putrescine levels in brain tumor patients","authors":"Enrico Pierangelli ,&nbsp;Victor A. Levin ,&nbsp;Jerome Seidenfeld ,&nbsp;Laurence J. Marton","doi":"10.1016/0014-2964(81)90028-1","DOIUrl":"10.1016/0014-2964(81)90028-1","url":null,"abstract":"<div><p>Cerebrospinal fluid (CSF) putrescine (Pu) levels are extremely useful measures of active tumor growth in patients harboring medulloblastoma but not in patients harboring most supratentorial malignant gliomas. This study was designed to determine the diffusion coefficient (<em>D</em>) for Pu in cat brain and the capillary permeability coefficient (<em>P</em><sub><em>c</em></sub>) in rat brain to explain the failure of supratentorial gliomas to manifest a consistent increase in CSF Pu with progressive tumor growth. The <em>P</em><sub><em>c</em></sub> for Pu was found to be greater than the <em>P</em><sub><em>c</em></sub> for urea, while the apparent brain <em>D</em> for Pu was lower than that for urea. This implies that Pu crosses capillaries and enters cells more rapidly than urea, which would reduce the amount of Pu that might ultimately reach the CSF by diffusion from tumor. These data explain why CSF levels of Pu are correlated best in medulloblastoms—generally located adjacent to the CSF pathways—and why levels are correlated least in malignant supratentorial gliomas—usually located within the brain hemispheres, from which diffusion to the ventricles and into the CSF would be difficult.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 2","pages":"Pages 143-147"},"PeriodicalIF":0.0,"publicationDate":"1981-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90028-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18276844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Growth pattern of a transplantable acute myeloid leukemia in the rat 大鼠可移植急性髓性白血病的生长模式
Pub Date : 1981-02-01 DOI: 10.1016/0014-2964(81)90038-4
Paolo Foa

A generalized acute myeloid leukemia was induced in inbred Sprague-Dawley rats by intravenous injection of chloroleukemia cells. In the bone marrow, colonization by blast cells was observed soon after transplantation and at the end of the disease leukemia cells accounted for about 70% of the whole cell population. In the peripheral blood, erythrocyte and platelet counts decreased late in the disease, while from day 5 onwards there was a progressive increase in the leukocyte count owing to blast cells released into the bloodstream. Spleen, liver and central nervous system were also involved in the disease. The survival time of transplanted animals correlated with the number of cells injected: after transplantation of 2 × 107 chloroleukemia cells survival time was 8.3 days, and with each 10-fold reduction of the inoculum survival time increased by about 2.5 days. The data presented show that Shay chloroleukemia mimics some features of human acute myeloid leukemia and possesses a predictable and highly reproducible growth rate, thus providing a further useful experimental model.

通过静脉注射绿白血病细胞诱导近交系Sprague-Dawley大鼠发生广泛性急性髓系白血病。在骨髓中,移植后不久就观察到胚细胞的定植,在疾病末期,白血病细胞约占整个细胞群的70%。在外周血中,红细胞和血小板计数在疾病晚期下降,而从第5天开始,由于胚细胞释放到血液中,白细胞计数逐渐增加。脾、肝、中枢神经系统也受累。移植动物的存活时间与注射细胞的数量相关:2 × 107个绿白血病细胞移植后存活时间为8.3天,接种量每减少10倍,存活时间增加约2.5天。结果表明,谢氏绿白血病模拟了人类急性髓系白血病的一些特征,具有可预测和高度可重复性的生长速率,从而为进一步提供了有用的实验模型。
{"title":"Growth pattern of a transplantable acute myeloid leukemia in the rat","authors":"Paolo Foa","doi":"10.1016/0014-2964(81)90038-4","DOIUrl":"10.1016/0014-2964(81)90038-4","url":null,"abstract":"<div><p>A generalized acute myeloid leukemia was induced in inbred Sprague-Dawley rats by intravenous injection of chloroleukemia cells. In the bone marrow, colonization by blast cells was observed soon after transplantation and at the end of the disease leukemia cells accounted for about <em>70</em>% of the whole cell population. In the peripheral blood, erythrocyte and platelet counts decreased late in the disease, while from <em>day 5</em> onwards there was a progressive increase in the leukocyte count owing to blast cells released into the bloodstream. Spleen, liver and central nervous system were also involved in the disease. The survival time of transplanted animals correlated with the number of cells injected: after transplantation of <em>2 × 10<sup>7</sup></em> chloroleukemia cells survival time was <em>8.3 days</em>, and with each <em>10</em>-fold reduction of the inoculum survival time increased by about <em>2.5 days</em>. The data presented show that Shay chloroleukemia mimics some features of human acute myeloid leukemia and possesses a predictable and highly reproducible growth rate, thus providing a further useful experimental model.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 2","pages":"Pages 211-216"},"PeriodicalIF":0.0,"publicationDate":"1981-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90038-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17993080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Structural derivatives of tamoxifen and oestradiol 3-methyl ether as potential alkylating antioestrogens 他莫昔芬和雌二醇3-甲基醚的结构衍生物作为潜在的烷基化抗雌激素
Pub Date : 1981-02-01 DOI: 10.1016/0014-2964(81)90036-0
V.C. Jordan , Linda Fenuik (born Rowsby) , Karen E. Allen , R.C. Cotton , Dora Richardson , A.L. Walpole , Jean Bowler

The oestrogenic and antioestrogenic activity of potential alkylating derivatives of tamoxifen and oestradiol 3-methyl ether have been compared with tamoxifen and oestradiol benzoate in the immature rat. Although all the tamoxifen derivatives demonstrated an ability to inhibit the binding of [3H]oestradiol to rabbit or rat uterine oestrogen receptors in vitro, none of the compounds was as potent as tamoxifen in tests for antioestrogenic activity in vivo. The potential alkylating derivatives of oestradiol 3-methyl ether were not antioestrogenic. The properties of all the compounds in vivo did not suggest irreversible effects upon the uterus. Since the assays in vitro did not predict activity in vivo the results indicate that only agents with very high affinity for the oestrogen receptor that do not potentially require metabolic activation may be useful in vivo.

本文比较了他莫昔芬和雌二醇3-甲基醚烷基化衍生物与他莫昔芬和雌二醇苯甲酸酯在未成熟大鼠体内的雌激素和抗雌激素活性。尽管所有的他莫昔芬衍生物在体外都显示出抑制[3H]雌二醇与家兔或大鼠子宫雌激素受体结合的能力,但在体内抗雌激素活性测试中,没有一种化合物比他莫昔芬更有效。雌二醇- 3-甲基醚的烷基化衍生物不具有抗雌激素作用。所有化合物在体内的性质并没有显示对子宫的不可逆影响。由于体外试验不能预测体内活性,因此结果表明,只有对雌激素受体具有非常高亲和力且不需要潜在代谢激活的药物才可能在体内有用。
{"title":"Structural derivatives of tamoxifen and oestradiol 3-methyl ether as potential alkylating antioestrogens","authors":"V.C. Jordan ,&nbsp;Linda Fenuik (born Rowsby) ,&nbsp;Karen E. Allen ,&nbsp;R.C. Cotton ,&nbsp;Dora Richardson ,&nbsp;A.L. Walpole ,&nbsp;Jean Bowler","doi":"10.1016/0014-2964(81)90036-0","DOIUrl":"10.1016/0014-2964(81)90036-0","url":null,"abstract":"<div><p>The oestrogenic and antioestrogenic activity of potential alkylating derivatives of tamoxifen and oestradiol 3-methyl ether have been compared with tamoxifen and oestradiol benzoate in the immature rat. Although all the tamoxifen derivatives demonstrated an ability to inhibit the binding of <em>[<sup>3</sup>H]</em>oestradiol to rabbit or rat uterine oestrogen receptors <em>in vitro</em>, none of the compounds was as potent as tamoxifen in tests for antioestrogenic activity <em>in vivo</em>. The potential alkylating derivatives of oestradiol <em>3</em>-methyl ether were not antioestrogenic. The properties of all the compounds <em>in vivo</em> did not suggest irreversible effects upon the uterus. Since the assays <em>in vitro</em> did not predict activity <em>in vivo</em> the results indicate that only agents with very high affinity for the oestrogen receptor that do not potentially require metabolic activation may be useful <em>in vivo</em>.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 2","pages":"Pages 193-200"},"PeriodicalIF":0.0,"publicationDate":"1981-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90036-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18276850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 18
Is better drug availability in secondary neoplasms responsible for better response to chemotherapy? 继发性肿瘤更好的药物可获得性是化疗反应更好的原因吗?
Pub Date : 1981-02-01 DOI: 10.1016/0014-2964(81)90037-2
M.G. Donelli , T. Colombo , G. Dagnino , M. Madonna , S. Garattini

The response of intramuscular Lewis Lung carcinoma (3LL) and its pulmonary metastases to graded doses of adriamycin (AM) was investigated in C57B1/6 mice given the drug i.v. 11 days after tumor implantation and the effect was quantitated by recording tumor or metastases weight at various intervals after treatment. In the same experimental tumor model the distribution of AM in primary and secondary neoplasms was studied by a fluorimetric procedure. The results indicate that, compared to the primary 3LL implant, AM has a much more pronounced effect on a percentage basis on the lung nodules, where the drug reaches 3–5 times the levels in the intramuscular tumor. In order to clarify the role of this better drug availability in determining the higher response at the metastic site, the experimental correlation law between AM amount (peak level or area under the concentration versus time curve, AUC) and the drug effect (the smallest ratio of mean tumor or metastases weights in treated to untreated animals) was investigated for both primary and secondary tumors, and the concentration-response curves thus constructed were compared with the dose-response curves. If the effect is related to drug concentration, there is definitely less difference between the response of intramuscular 3LL and its metastases to AM and it even disappears at certain concentrations. The ed50 for the primary tumor is 10 times higher than for the lung nodules if derived from the dose-response curve, and only 2–3 times higher if derived from the concentration-response curve. Moreover, the lack of linear relationship and the biexponential correlation between the variables of effect and dose or peak concentration or AUC, either for the intramuscular or pulmonary 3LL, indicates that the effect does not increase proportionally to the drug amounts, suggesting that other factors beside AM concentration may contribute to the better drug response at the metastatic site.

研究了C57B1/6小鼠在肿瘤植入后11天静脉注射阿霉素对肌内Lewis肺癌(3LL)及其肺转移灶的影响,并通过记录治疗后不同时间间隔的肿瘤或转移灶重量来量化其作用。在同一实验肿瘤模型中,用荧光法研究了AM在原发性和继发性肿瘤中的分布。结果表明,与初级3LL植入物相比,AM对肺结节的百分比影响更为明显,其中药物达到肌肉内肿瘤水平的3-5倍。为了阐明这种更好的药物可利用性在确定转移部位更高反应中的作用,我们研究了原发性和继发性肿瘤中AM量(浓度与时间曲线下的峰值水平或面积,AUC)与药物效果(治疗动物与未治疗动物平均肿瘤或转移重量的最小比值)之间的实验相关规律。并将所构建的浓度-响应曲线与剂量-响应曲线进行比较。如果这种效应与药物浓度有关,那么肌内3LL的反应与转移到AM之间的差异肯定较小,甚至在一定浓度下消失。根据剂量-反应曲线,原发性肿瘤的ed50比肺结节高10倍,而根据浓度-反应曲线,ed50仅比肺结节高2-3倍。此外,肌内或肺内3LL的效应变量与剂量、峰值浓度或AUC之间缺乏线性关系和双指数相关性,表明效应不随药物量成比例地增加,提示除AM浓度外的其他因素可能有助于转移部位更好的药物反应。
{"title":"Is better drug availability in secondary neoplasms responsible for better response to chemotherapy?","authors":"M.G. Donelli ,&nbsp;T. Colombo ,&nbsp;G. Dagnino ,&nbsp;M. Madonna ,&nbsp;S. Garattini","doi":"10.1016/0014-2964(81)90037-2","DOIUrl":"10.1016/0014-2964(81)90037-2","url":null,"abstract":"<div><p>The response of intramuscular Lewis Lung carcinoma (3LL) and its pulmonary metastases to graded doses of adriamycin (AM) was investigated in <em>C57B1/6</em> mice given the drug i.v. <em>11 days</em> after tumor implantation and the effect was quantitated by recording tumor or metastases weight at various intervals after treatment. In the same experimental tumor model the distribution of AM in primary and secondary neoplasms was studied by a fluorimetric procedure. The results indicate that, compared to the primary 3LL implant, AM has a much more pronounced effect on a percentage basis on the lung nodules, where the drug reaches <em>3–5</em> times the levels in the intramuscular tumor. In order to clarify the role of this better drug availability in determining the higher response at the metastic site, the experimental correlation law between AM amount (peak level or area under the concentration versus time curve, AUC) and the drug effect (the smallest ratio of mean tumor or metastases weights in treated to untreated animals) was investigated for both primary and secondary tumors, and the concentration-response curves thus constructed were compared with the dose-response curves. If the effect is related to drug concentration, there is definitely less difference between the response of intramuscular 3LL and its metastases to AM and it even disappears at certain concentrations. The <em><span>ed</span><sub>50</sub></em> for the primary tumor is <em>10</em> times higher than for the lung nodules if derived from the dose-response curve, and only 2–3 times higher if derived from the concentration-response curve. Moreover, the lack of linear relationship and the biexponential correlation between the variables of effect and dose or peak concentration or AUC, either for the intramuscular or pulmonary 3LL, indicates that the effect does not increase proportionally to the drug amounts, suggesting that other factors beside AM concentration may contribute to the better drug response at the metastatic site.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 2","pages":"Pages 201-209"},"PeriodicalIF":0.0,"publicationDate":"1981-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90037-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18276851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Current results of the screening program at the division of cancer treatment, national cancer institute 国家癌症研究所癌症治疗部的筛查项目的最新结果
Pub Date : 1981-02-01 DOI: 10.1016/0014-2964(81)90027-X
Abraham Goldin , John M. Venditti , John S. Macdonald , Franco M. Muggia , Jane E. Henney , Vincent T. Devita Jr.

The prospective screening program at the Division of Cancer Treatment, National Cancer Institute, has now been in operation for several years and is making steady progress in the identification of new synthetic compounds and natural products of potential interest for the clinic. Data are presented on four categories of drugs that have been tested in the new screening panel: (a) clinically established antitumor agents; (b) new drugs and drugs for which there is renewed clinical interest based on activity in the new screen and previously inadequate clinical trial; (c) drugs in the initial phases of clinical trial; (d) compounds in development. An analysis of the data is presented, taking into account a series of important questions that are being addressed prospectively to the new screen. Although the ability to provide definitive answers must await feedback from clinical testing of compounds recommended by the screen, some generalizations appear to be emerging, and these are discussed. A comparison is made of the activity of drugs in the treatment of human tumors growing in two sites, subcutaneously and under the renal capsule. The subrenal capsule model appears to be somewhat more sensitive to drugs than the subcutaneous model and may provide certain advantages for initial panel testing. Attention is drawn to the potential usefulness in a screening program of the newly developed clonogenic techniques for growing human tumors. The screening program at the Division of Cancer Treatment is viewed as a dynamic entity, subject to modification in accordance with acquired experience.

美国国家癌症研究所癌症治疗部的前瞻性筛查项目已经运行了几年,在鉴定新的合成化合物和临床潜在兴趣的天然产物方面取得了稳步进展。数据介绍了在新的筛选小组中测试的四类药物:(a)临床建立的抗肿瘤药物;(b)新药和基于新筛选活动和先前不充分的临床试验而重新引起临床兴趣的药物;(c)处于临床试验初期的药物;(d)正在开发的化合物。提出了对数据的分析,考虑到新屏幕正在解决的一系列重要问题。虽然提供明确答案的能力必须等待筛选推荐的化合物的临床试验反馈,但一些概括似乎正在出现,并对其进行讨论。比较了药物治疗生长在皮下和肾包膜下两个部位的人类肿瘤的活性。与皮下模型相比,肾下胶囊模型似乎对药物更敏感,可能为初始面板试验提供某些优势。注意到潜在的有用性,在筛选程序的新开发的克隆技术生长的人类肿瘤。癌症治疗部门的筛查项目被视为一个动态的实体,可以根据获得的经验进行修改。
{"title":"Current results of the screening program at the division of cancer treatment, national cancer institute","authors":"Abraham Goldin ,&nbsp;John M. Venditti ,&nbsp;John S. Macdonald ,&nbsp;Franco M. Muggia ,&nbsp;Jane E. Henney ,&nbsp;Vincent T. Devita Jr.","doi":"10.1016/0014-2964(81)90027-X","DOIUrl":"10.1016/0014-2964(81)90027-X","url":null,"abstract":"<div><p>The prospective screening program at the Division of Cancer Treatment, National Cancer Institute, has now been in operation for several years and is making steady progress in the identification of new synthetic compounds and natural products of potential interest for the clinic. Data are presented on four categories of drugs that have been tested in the new screening panel: (a) clinically established antitumor agents; (b) new drugs and drugs for which there is renewed clinical interest based on activity in the new screen and previously inadequate clinical trial; (c) drugs in the initial phases of clinical trial; (d) compounds in development. An analysis of the data is presented, taking into account a series of important questions that are being addressed prospectively to the new screen. Although the ability to provide definitive answers must await feedback from clinical testing of compounds recommended by the screen, some generalizations appear to be emerging, and these are discussed. A comparison is made of the activity of drugs in the treatment of human tumors growing in two sites, subcutaneously and under the renal capsule. The subrenal capsule model appears to be somewhat more sensitive to drugs than the subcutaneous model and may provide certain advantages for initial panel testing. Attention is drawn to the potential usefulness in a screening program of the newly developed clonogenic techniques for growing human tumors. The screening program at the Division of Cancer Treatment is viewed as a dynamic entity, subject to modification in accordance with acquired experience.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 2","pages":"Pages 129-142"},"PeriodicalIF":0.0,"publicationDate":"1981-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90027-X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17944178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 217
An explanation for the S-phase specificity of the cytotoxicity of protein synthesis inhibitors 解释蛋白质合成抑制剂的细胞毒性的s期特异性
Pub Date : 1981-02-01 DOI: 10.1016/0014-2964(81)90033-5
D.M. Woodcock, J.K. Adams, I.A. Cooper

A pulse of the protein synthesis inhibitor cycloheximide is shown to induce chromosome aberrations in cultured cells of human origin. These aberrations do not appear until in excess of 12 hr after the pulse and their appearance coincides with the time when cells which had been in S-phase at the time of the cycloheximide pulse reach mitosis. We suggest that the reason why the protein synthesis inhibitor cycloheximide has previously been reported not to induce chromosome aberrations is due to the long delay of cells with damaged chromosomes in reaching mitosis.

蛋白质合成抑制剂环己亚胺的脉冲显示诱导染色体畸变的培养细胞的人类来源。这些畸变直到脉冲后超过12小时才出现,它们的出现与在环己亚胺脉冲时处于s期的细胞达到有丝分裂的时间一致。我们认为,以前报道的蛋白质合成抑制剂环己亚胺不诱导染色体畸变的原因是由于染色体受损的细胞达到有丝分裂的时间较长。
{"title":"An explanation for the S-phase specificity of the cytotoxicity of protein synthesis inhibitors","authors":"D.M. Woodcock,&nbsp;J.K. Adams,&nbsp;I.A. Cooper","doi":"10.1016/0014-2964(81)90033-5","DOIUrl":"10.1016/0014-2964(81)90033-5","url":null,"abstract":"<div><p>A pulse of the protein synthesis inhibitor cycloheximide is shown to induce chromosome aberrations in cultured cells of human origin. These aberrations do not appear until in excess of <em>12 hr</em> after the pulse and their appearance coincides with the time when cells which had been in S-phase at the time of the cycloheximide pulse reach mitosis. We suggest that the reason why the protein synthesis inhibitor cycloheximide has previously been reported not to induce chromosome aberrations is due to the long delay of cells with damaged chromosomes in reaching mitosis.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 2","pages":"Pages 173-177"},"PeriodicalIF":0.0,"publicationDate":"1981-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90033-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18276847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Vindesine therapy in melphalan-resistant multiple myeloma 长春地辛治疗抗melphalan多发性骨髓瘤
Pub Date : 1981-02-01 DOI: 10.1016/0014-2964(81)90040-2
B. Houwen, Th. Ockhuizen, J. Marrink, H.O. Nieweg

Vindesine, a new vinca alkaloid, was administered in thirteen patients with advanced multiple myeloma (stages IIIA and IIIB), resistant to alkylating agents. Eleven patients received two complete courses and could be evaluated. Six patients (55%) showed objective improvement. This was indicated by a decrease of greater than 50% of pretreatment myeloma protein serum levels, normalization of elevated serum calcium levels, and improvement of haemoglobin concentration and renal function. Neutropenia of short duration, mild paraesthesias and alopecia were noted as side effects.

Vindesine是一种新的长春花生物碱,对13例对烷基化剂耐药的晚期多发性骨髓瘤(IIIA期和IIIB期)患者进行了治疗。11例患者接受了两个完整疗程,并可进行评估。客观改善6例(55%)。这表明,预处理骨髓瘤蛋白血清水平下降50%以上,血清钙水平升高正常化,血红蛋白浓度和肾功能改善。副作用为中性粒细胞减少、轻度感觉异常和脱发。
{"title":"Vindesine therapy in melphalan-resistant multiple myeloma","authors":"B. Houwen,&nbsp;Th. Ockhuizen,&nbsp;J. Marrink,&nbsp;H.O. Nieweg","doi":"10.1016/0014-2964(81)90040-2","DOIUrl":"10.1016/0014-2964(81)90040-2","url":null,"abstract":"<div><p>Vindesine, a new vinca alkaloid, was administered in thirteen patients with advanced multiple myeloma (stages <em>IIIA</em> and <em>IIIB</em>), resistant to alkylating agents. Eleven patients received two complete courses and could be evaluated. Six patients (<em>55%</em>) showed objective improvement. This was indicated by a decrease of greater than <em>50%</em> of pretreatment myeloma protein serum levels, normalization of elevated serum calcium levels, and improvement of haemoglobin concentration and renal function. Neutropenia of short duration, mild paraesthesias and alopecia were noted as side effects.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 2","pages":"Pages 227-232"},"PeriodicalIF":0.0,"publicationDate":"1981-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90040-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18276852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 19
Fc and C3 receptor patterns on two EBV-negative burkitt lymphoma lines during acute exposure to EBV (P3HR-1 substrain) 急性暴露于EBV (P3HR-1亚株)时两种EBV阴性伯基特淋巴瘤株的Fc和C3受体模式
Pub Date : 1981-02-01 DOI: 10.1016/0014-2964(81)90031-1
Viggo Jønsson , Georg Klein

Exposure of the two EBV-negative Burkitt lymphoma lines, BJAB and Ramos, to the abortively cytopathic P3HR-1 substrain of EBV led to an increased expression of C3 receptors within the first twelve weeks. At the twelfth week, 100% of cells carried a high concentration of C3 receptors in both lines. Compared with the receptor pattern of BJAB and Ramos after chronic virus exposure it was seen that after the twelfth week some of the C3 receptors vanished while a certain number of Fc receptors reappeared. These changes in the surface markers are regarded as part of the multiple changes found during exposure to P3HR-1 virus. Apparently, the superinfection initiates a progressive maturation of the cells and the increase of C3 receptors is regarded as an expression of a ‘switch to the right’ in the B-cell differentiation pathway.

将两种EBV阴性伯基特淋巴瘤系(BJAB和Ramos)暴露于EBV致细胞病变的P3HR-1亚株后,在前12周内导致C3受体的表达增加。12周时,两系100%的细胞携带高浓度的C3受体。与慢性病毒暴露后BJAB和Ramos的受体模式比较,发现12周后部分C3受体消失,而一定数量的Fc受体重新出现。这些表面标记物的变化被认为是暴露于P3HR-1病毒期间发现的多种变化的一部分。显然,重复感染启动了细胞的渐进式成熟,C3受体的增加被认为是b细胞分化途径中“向右切换”的表达。
{"title":"Fc and C3 receptor patterns on two EBV-negative burkitt lymphoma lines during acute exposure to EBV (P3HR-1 substrain)","authors":"Viggo Jønsson ,&nbsp;Georg Klein","doi":"10.1016/0014-2964(81)90031-1","DOIUrl":"10.1016/0014-2964(81)90031-1","url":null,"abstract":"<div><p>Exposure of the two EBV-negative Burkitt lymphoma lines, BJAB and Ramos, to the abortively cytopathic <em>P3HR-1</em> substrain of EBV led to an increased expression of <em>C3</em> receptors within the first twelve weeks. At the twelfth week, <em>100%</em> of cells carried a high concentration of <em>C3</em> receptors in both lines. Compared with the receptor pattern of BJAB and Ramos after chronic virus exposure it was seen that after the twelfth week some of the <em>C3</em> receptors vanished while a certain number of Fc receptors reappeared. These changes in the surface markers are regarded as part of the multiple changes found during exposure to <em>P3HR-1</em> virus. Apparently, the superinfection initiates a progressive maturation of the cells and the increase of <em>C3</em> receptors is regarded as an expression of a ‘switch to the right’ in the B-cell differentiation pathway.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 2","pages":"Pages 161-165"},"PeriodicalIF":0.0,"publicationDate":"1981-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90031-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17330356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Radioimmunoassay of urokinase for quantification of plasminogen activators released in ovarian tumour cultures 尿激酶放射免疫法定量测定卵巢肿瘤培养物中释放的纤溶酶原激活剂
Pub Date : 1981-02-01 DOI: 10.1016/0014-2964(81)90042-6
Birger Åstedt , Lars Holmberg , Ingegerd Lecander , Jan Thorell

A radioimmunoassay was developed with an urokinase antiserum and radioiodinated DFP-inactivated urokinase of 31,000 daltons. Assays of tissue culture medium from ovarian tumours and fetal kidneys showed the presence of urokinase-like immunoreactivity, which could be separated in three molecular forms at gel filtration. All three forms showed inhibition curves parallel to that of purified urokinase. The concentration obtained by the assay corresponded to the enzymatic activity. Distinctly parallel curves were found for tumour cultures of various ages in which the three molecular forms differed in their relative concentrations.

用尿激酶抗血清和31,000道尔顿的放射性碘化dfp灭活尿激酶进行放射免疫测定。对卵巢肿瘤和胎儿肾脏组织培养基的分析显示存在尿激酶样免疫反应性,在凝胶过滤下可以以三种分子形式分离。这三种形式的抑制曲线与纯化的尿激酶相似。测定得到的浓度与酶的活性相对应。在不同年龄的肿瘤培养物中发现了明显的平行曲线,其中三种分子形式的相对浓度不同。
{"title":"Radioimmunoassay of urokinase for quantification of plasminogen activators released in ovarian tumour cultures","authors":"Birger Åstedt ,&nbsp;Lars Holmberg ,&nbsp;Ingegerd Lecander ,&nbsp;Jan Thorell","doi":"10.1016/0014-2964(81)90042-6","DOIUrl":"10.1016/0014-2964(81)90042-6","url":null,"abstract":"<div><p>A radioimmunoassay was developed with an urokinase antiserum and radioiodinated DFP-inactivated urokinase of <em>31,000 daltons</em>. Assays of tissue culture medium from ovarian tumours and fetal kidneys showed the presence of urokinase-like immunoreactivity, which could be separated in three molecular forms at gel filtration. All three forms showed inhibition curves parallel to that of purified urokinase. The concentration obtained by the assay corresponded to the enzymatic activity. Distinctly parallel curves were found for tumour cultures of various ages in which the three molecular forms differed in their relative concentrations.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 2","pages":"Pages 239-244"},"PeriodicalIF":0.0,"publicationDate":"1981-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90042-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18068258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 46
Lactation and breast cancer. Are they unrelated? 哺乳期和乳腺癌。它们是无关的吗?
Pub Date : 1981-02-01 DOI: 10.1016/0014-2964(81)90046-3
Patricia Cohen, Douglas Dix
{"title":"Lactation and breast cancer. Are they unrelated?","authors":"Patricia Cohen,&nbsp;Douglas Dix","doi":"10.1016/0014-2964(81)90046-3","DOIUrl":"10.1016/0014-2964(81)90046-3","url":null,"abstract":"","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 2","pages":"Pages 259-260"},"PeriodicalIF":0.0,"publicationDate":"1981-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90046-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18276857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
European Journal of Cancer (1965)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1